Invivyd to Participate in Upcoming Investor Conferences

Rhea-AI Impact
Rhea-AI Sentiment
(Very Negative)
Rhea-AI Summary
Invivyd, Inc. to present at investor conferences
  • None.
  • None.

WALTHAM, Mass., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD), a clinical-stage biopharmaceutical company on a mission to protect the vulnerable from serious viral infectious diseases, today announced that it will present at the following investor conferences:

H.C. Wainwright 25th Annual Global Investment Conference
Fireside Chat Date: Monday, September 11, 2023
Fireside Chat Time: 3:00 PM ET
Location: New York, NY

Morgan Stanley 21st Annual Global Healthcare Conference
Fireside Chat Date: Wednesday, September 13, 2023
Fireside Chat Time: 12:55 PM ET
Location: New York, NY

Live webcasts of the fireside chats will be available in the investor section of the company's website at and will be archived for approximately 90 days following the events.

About Invivyd
Invivyd, Inc. (Nasdaq: IVVD) is a biopharmaceutical company on a mission to rapidly and perpetually deliver antibody-based therapies that protect vulnerable people from the devastating consequences of circulating viral threats, beginning with SARS-CoV-2. ​​Invivyd’s technology works at the intersection of evolutionary virology, predictive modeling, and antibody engineering, and is designed to identify high-quality, long-lasting antibodies with the potential to resist viral escape. The company is generating a robust pipeline of product candidates which could be used in prevention or treatment of serious viral diseases, starting with COVID-19 and expanding into influenza and other high-need indications. Visit to learn more.


Scott Young
(781) 208-1747

Gabriella Linville-Engler
(781) 208-0160

Invivyd Inc


IVVD Rankings

IVVD Latest News

IVVD Stock Data

Biological Product (except Diagnostic) Manufacturing

About IVVD

adagio is developing best-in-class antibodies that can broadly neutralize sars-cov-2, sars-cov-1 and additional potentially emergent coronaviruses. we believe our antibodies will match or exceed the potency and coverage of conventional sars-cov-2 antibody programs and can be used as both therapeutic and durable prophylactic treatments. our candidates are engineered using best-in-industry antibody discovery capabilities and are designed to maximize potency and duration of effect. our portfolio includes multiple, non-competing antibodies with distinct binding targets, enabling a strategy that can avoid viral escape. our lead program is expected to enter the clinic by the end of 2020.